2. Disease Areas
  3. Infection
  4. HIV Infection

HIV Infection

Acute HIV infection is a self-limited phase occurring within the first few weeks after initial exposure to the human immunodeficiency virus (HIV), marked by rapid viral replication, high viral loads, and nonspecific symptoms such as fever, rash, and lymphadenopathy. This stage may last from days to over 10 weeks, during which the immune system begins to mount a response. Early diagnosis is critical for initiating timely treatment and reducing transmission risk. HIV infection is associated with acquired immunodeficiency syndrome (AIDS) and has links to other infectious diseases like syphilis. The CCR5 gene plays a key role in HIV pathogenesis, and related biological pathways include the Innate Immune System and ERK Signaling. Drugs such as Candesartan cilexetil and Lercanidipine have been studied in this context. Affected tissues include T cells and breast tissue, with associated phenotypes involving cellular dysfunction and neoplastic changes.

 

HIV Infection (123):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0522A
    Ampicillin sodium 69-52-3 98.0%
    Ampicillin sodium (D-(-)-α-Aminobenzylpenicillin sodium salt) is a broad-spectrum beta-lactam antibiotic against a variety of gram-positive and gram-negative bacteria.
    Ampicillin sodium
  • HY-11101
    Alendronate sodium hydrate 121268-17-5 98.0%
    Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with IC50 of 460 nM.
    Alendronate sodium hydrate
  • HY-131166
    Curdlan 54724-00-4 98.5%
    Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages. Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases.
    Curdlan
  • HY-17367
    Atazanavir 198904-31-3 99.23%
    Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir
  • HY-P990297
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) 99.5%
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV.
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5)
  • HY-114506
    trans-​2-​Methoxycinnamic acid 1011-54-7 99.06%
    trans-2-Methoxycinnamic acid (Compound 6) is a trans-cinnamic acid (HY-N0610) derivative. trans-2-Methoxycinnamic acid inhibits α-glucosidase with an IC50 of 4.34 mM. trans-2-Methoxycinnamic acid can be used in the research of HIV infection and hyperglycemia.
    trans-​2-​Methoxycinnamic acid
  • HY-183988
    OICR409946
    OICR409946 is a self-dimerization-induced proximity-targeting chimera (SDIPTAC) targeting DCAF1, with a Kd value of 6200 nM. OICR409946 binds to DCAF1, induces head-to-tail homodimerization, sterically blocks the Vpr binding interface, prevents the recruitment of Vpr to the CRL4DCAF1 complex, and inhibits Vpr-dependent HIV replication. OICR409946 can be used in studies related to HIV infection (DCAF1 ligand: (HY-169390); Linker: (HY-130659)).
    OICR409946
  • HY-126120
    BILA 1906 BS 154612-31-4
    BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection.
    BILA 1906 BS
  • HY-160229
    ssRNA40 sodium 98.34%
    ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders.
    ssRNA40 sodium
  • HY-W020658
    L-α-Phosphatidylinositol 97281-52-2
    L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection.
    L-α-Phosphatidylinositol
  • HY-W037893
    CHMA1004 dihydrochloride 122323-88-0 99.38%
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection.
    CHMA1004 dihydrochloride
  • HY-125474
    Carrageenan 9000-07-1
    Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
    Carrageenan
  • HY-18257
    Rolitetracycline 751-97-3 ≥98.0%
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease.
    Rolitetracycline
  • HY-P991069
    VRC-01 1412901-55-3 99.805%
    VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection.
    VRC-01
  • HY-W012166
    N-Succinimidyl bromoacetate 42014-51-7 99.20%
    N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme.
    N-Succinimidyl bromoacetate
  • HY-W010937
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide 174899-83-3 99.91%
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMIM-TFSI; BMI-TFSI) is an HIV-1 integrase inhibitor. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide weakly inhibits recombinant HIV-1 integrase 3'-processing or strand transfer activity. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide can be used for the research of HIV-1.
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide
  • HY-D0976
    NF279 202983-32-2 98.5%
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
    NF279
  • HY-142989
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine 99296-81-8 ≥98.0%
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia.
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine
  • HY-P4076
    MPG peptides, Pβ 791642-10-9 98.26%
    MPG peptides, Pβ is an amphipathic cell-penetrating peptide. MPG peptides, Pβ consists of three components: the hydrophobic fusion sequence (GALFLGFLGAAGSTMGA) of HIV glycoprotein 41, a spacer domain (WSQP), and the nuclear localization signal (KKKRKV) of the large T antigen of Simian virus 40. MPG peptides, Pβ can form stable non-covalent complexes with nucleic acids (including DNA) through electrostatic interactions and improve their intracellular delivery. MPG peptides, Pβ can be used in studies of HIV-1-related immune responses.
    MPG peptides, Pβ
  • HY-N2188
    Beta-Acetoxyisovalerylshikonin 69091-17-4 99.57%
    Beta-Acetoxyisovalerylshikonin is a naturally occurring naphthoquinone-type shikonin derivative that is widely distributed in the roots and cell suspension cultures of *Arnebia euchroma*, *Arnebia guttata*, *Onosma hispidum* and *Lithospermum erythrorhizon*. Beta-Acetoxyisovalerylshikonin exhibits favorable antibacterial, anti-inflammatory, wound-healing promoting and antioxidant activities, and also possesses potential anti-tumor and anti-HIV properties.
    Beta-Acetoxyisovalerylshikonin